These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 25033247)
1. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Jost C; Plückthun A Curr Opin Struct Biol; 2014 Aug; 27():102-12. PubMed ID: 25033247 [TBL] [Abstract][Full Text] [Related]
2. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion. Lu D; Zhu Z Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843 [TBL] [Abstract][Full Text] [Related]
3. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Vincent KJ; Zurini M Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076 [TBL] [Abstract][Full Text] [Related]
4. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237 [TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody derivatives based on full-length IgG formats. Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106 [TBL] [Abstract][Full Text] [Related]
6. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564 [TBL] [Abstract][Full Text] [Related]
8. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542 [TBL] [Abstract][Full Text] [Related]
9. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies. Dimasi N; Fleming R; Wu H; Gao C Methods; 2019 Feb; 154():77-86. PubMed ID: 30102989 [TBL] [Abstract][Full Text] [Related]
10. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. Golay J; Choblet S; Iwaszkiewicz J; Cérutti P; Ozil A; Loisel S; Pugnière M; Ubiali G; Zoete V; Michielin O; Berthou C; Kadouche J; Mach JP; Duonor-Cérutti M J Immunol; 2016 Apr; 196(7):3199-211. PubMed ID: 26921308 [TBL] [Abstract][Full Text] [Related]
11. A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture. Wang C; Vemulapalli B; Cao M; Gadre D; Wang J; Hunter A; Wang X; Liu D MAbs; 2018; 10(8):1226-1235. PubMed ID: 30153083 [TBL] [Abstract][Full Text] [Related]
12. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties. Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329 [TBL] [Abstract][Full Text] [Related]
13. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles. Mabry R; Snavely M IDrugs; 2010 Aug; 13(8):543-9. PubMed ID: 20721825 [TBL] [Abstract][Full Text] [Related]
15. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918 [TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies for cancer therapy. Hollander N Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943 [TBL] [Abstract][Full Text] [Related]
17. Current perspectives of bispecific antibody-based immunotherapy. Talac R; Nelson H J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049 [TBL] [Abstract][Full Text] [Related]
18. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Gu J; Ghayur T Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980 [TBL] [Abstract][Full Text] [Related]
19. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695 [TBL] [Abstract][Full Text] [Related]
20. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. Dengl S; Sustmann C; Brinkmann U Immunol Rev; 2016 Mar; 270(1):165-77. PubMed ID: 26864111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]